Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors

Vopec Pharmaceuticals and Agastiya Biotech announce results from the Phase 1 study of AB001, an investigational small molecule PDL1 immunotherapy for patients with metastasized and locally advanced solid tumors.  Unlike current standard-of-care immuno- and chemotherapy drugs AB001’s novel immunotherapy mechanism of action selectively destroys tumors without harming healthy cells.  Read more on the breakthrough toxicity and efficacy of AB001 on multiple metastatic cancers.

The US FDA has awarded Orphan Drug Designations for Glioblastoma, Pancreatic and Acute Myeloid Leukemia indications for AB001.   These rare cancers are generally considered a death sentence.  AB001 may prove to be the answer.

At Agastiya create negligibly / toxicity-free small molecules, an unmet need of the pharmaceutical industry. Toxicity is the biggest challenge in drug discovery. It not only delays the drug approval process but results in less efficacy and drives up drug costs.

Our impressive portfolio of small molecules has no toxicity/negligible toxicity covering a wide variety of cancer indications, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia, depression, diabetes, life extension telomere technology, and others.